Torrent Pharmaceuticals
3,252.50
-6.30(-0.19%)
Market Cap₹1,10,079.38 Cr
PE Ratio57.23
IndustryHealthcare
Company Performance:
1D-0.19%
1M+0.51%
6M-2.79%
1Y+13.13%
5Y+164.09%
View Company Insightsright
Latest news about Torrent Pharmaceuticals
Torrent Pharmaceuticals: Q4 Profit Up 11%, Plans Rs 5,000-Crore Fundraise May 20, 2025
Torrent Pharma to Explore Fundraising Options in Upcoming Board Meeting May 13, 2025
Torrent Pharmaceuticals Raises ₹200 Crore Through Commercial Paper Issuance Mar 27, 2025
Torrent Pharmaceuticals Raises ₹200 Crore Through Commercial Paper Issue Mar 26, 2025
More news about Torrent Pharmaceuticals
25Mar 25
Torrent Pharmaceuticals Raises ₹300 Crore Through Commercial Paper Issue
Torrent Pharmaceuticals has issued commercial papers worth ₹300 crore with a 90-day tenure. The papers, allotted on March 25, 2025, will mature on June 23, 2025, carrying a 7.13% per annum coupon rate. They are unsecured and proposed to be listed on the National Stock Exchange of India. This move demonstrates the company's strong financial position and efficient access to capital markets, potentially aimed at optimizing cash management or funding short-term operational needs.
10Mar 25
Torrent Pharma to Launch Affordable Diabetes Medication, Boosting Treatment Accessibility
Torrent Pharmaceuticals Ltd is planning to introduce an affordable version of empagliflozin, a vital medication for type 2 diabetes. This move is part of a broader initiative by Indian pharmaceutical companies to improve access to essential medications. The launch of low-cost empagliflozin is expected to enhance accessibility for a larger diabetic population, potentially reshape the diabetes care market in India, and increase competition while reducing overall treatment costs.
28Feb 25
Torrent Pharma Set for $43 Million Inflow as MSCI India Index Weightage Increases
Torrent Pharmaceuticals' weightage in the MSCI India Standard Index is set to increase, potentially triggering a $43 million (Rs 3.76 billion) inflow into the stock. This adjustment, effective today at 3 PM, is expected to boost liquidity and attract more passive funds and index-tracking investors. Separately, Pranav Mehta, Executive Director (Strategic Planning), has resigned effective February 26, 2025, to pursue new career opportunities.
Torrent Pharmaceuticals
3,252.50
-6.30
(-0.19%)
1 Year Returns:+13.13%
Industry Peers
Sun Pharmaceutical
1,687.80
(+0.02%)
Divis Laboratories
6,667.00
(-0.86%)
Cipla
1,505.20
(+0.16%)
Dr Reddys Laboratories
1,362.50
(-0.01%)
Torrent Pharmaceuticals
3,252.50
(-0.19%)
Mankind Pharma
2,381.30
(-0.36%)
Zydus Life Science
974.95
(-0.39%)
Lupin
1,999.60
(-1.17%)
Abbott
31,515.00
(-0.19%)
Aurobindo Pharma
1,150.20
(-0.43%)